All In MedTech

Device Trial Radar · NCT03746132

Oxygen for Vascular Incisional Healing

A Prospective, Randomized, Crossover Study of Transdermal, Continuous Oxygen Therapy for Surgical Site Wound Healing in High- Risk Subjects Undergoing Lower Extremity Revascularization

Last checked: Nov 20, 2026Latest source record: Sep 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 7, 2019

Primary completion

Jul 31, 2022

Study completion Jul 31, 2022

Sponsor

Lead sponsor
Neogenix, LLC dba OgenixNot on our public-company list
Sponsor type
Industry
Collaborators
University of Maryland, College Park
First posted
Nov 19, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate Transdermal Continuous Oxygen Therapy (TCOT) as an adjunct to surgical wound healing in subjects undergoing vascular surgery for lower extremity arterial occlusive disease. It is the intention of this study to administer oxygen using the TCOT approach to the surgical sites of subjects undergoing the surgery and to monitor the healing of the incision as well as infection rate. The hypothesis is that oxygen delivered transdermally to the surgical site in a continuous manner for up to 28 days will accelerate the healing process and reduce the infection rate compared to the Standard of Care.

Conditions

  • Surgical Wound Healing
  • Lower Extremity
  • Revascularization
  • Incision

Interventions

  • EPIFLODevice

    EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. surgical wound closure assessed using modified Bates-Jenson Wound Assessment ToolTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.